Stocktoria
Quanterix Corp QTRX
Quanterix Corp (QTRX) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $138.9M at a -77.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -0.62 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.328 |
| Retained earnings / assets | -1.378 |
| EBIT / assets | -0.3 |
| Equity / liabilities | 2.404 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| QTRX | Quanterix Corp | 1/9 | -1.83 | — | +1.1% |
| PACB | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | 3/9 | -13.42 | — | +3.9% |
| HBIO | HARVARD BIOSCIENCE INC | 4/9 | -10.45 | — | -8.1% |
| CTKB | Cytek Biosciences, Inc. | 3/9 | 6.15 | — | +0.5% |
| PRPO | Precipio, Inc. | 7/9 | -13.13 | — | +28% |
| RPID | RAPID MICRO BIOSYSTEMS, INC. | 2/9 | — | — | +19.7% |
| EYPT | EyePoint, Inc. | 1/9 | -3.58 | — | -27.5% |
About Quanterix Corp
Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
FAQ
Is QTRX financially healthy?
Quanterix Corp's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does QTRX pay a dividend?
No, Quanterix Corp does not currently pay a dividend.
How profitable is QTRX?
In FY2025, Quanterix Corp had a net margin of -77.1% and a return on equity of -36.2%.
What is the analyst price target for QTRX?
The average Wall-Street price target for Quanterix Corp is $4.33, about 47.9% above the recent price, from 3 analysts (consensus: hold).
Is QTRX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Quanterix Corp: a Piotroski F-score of 1/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.